Achilles Therapeutics (ACHL) to Release Earnings on Tuesday

Achilles Therapeutics plc (ACHL), a clinical-stage biopharmaceutical company based in London, UK, is set to release its financial results and business updates for the third quarter ended September 30, 2022, on Tuesday, November 8, 2022. The company focuses on developing precision T-cell therapies for the treatment of solid tumors.

ACHL's precision T-cell therapy platform is designed to target clonally-expanded tumor-specific T-cells, which are derived from a patient's own immune system. This approach aims to address the limitations of current immunotherapies by targeting tumors with high precision and reducing the risk of graft-versus-host disease and other adverse effects.

The company's lead product candidate, known as DP101, is currently being evaluated in a Phase I/II trial called CHRIS (Clonally-expanded HLA-matched T-cells Targeting Neoantigens in Solid Tumors). This trial is designed to assess the safety, tolerability, and efficacy of DP101 in patients with advanced solid tumors that have progressed following standard treatment options.

ACHL has reportedly dosed its first patient in a new cohort of the CHRIS trial in August 2022, expanding the study to include patients with non-small cell lung cancer (NSCLC) and other solid tumors. The company also announced that it had received clearance from the U.S. Food and Drug Administration (FDA) for a Phase I/II trial of DP101 in combination with Merck & Co.'s (MRK) Keytruda (pembrolizumab) in patients with advanced solid tumors.

In addition to its clinical programs, Achilles Therapeutics has also made progress in expanding its intellectual property portfolio. In October 2022, the company announced that it had been granted a new patent in Europe for its precision T-cell therapy platform.

The upcoming earnings report will provide investors with an update on the progress of these clinical trials, as well as any potential collaborations or partnerships that may have been established since the last report. Additionally, management will likely discuss financials, including revenue, expenses, and cash burn rates, as well as any potential future funding sources or financing plans.

Investors and industry observers will be closely watching this report for any updates on the progress of DP101 and its potential impact on the competitive landscape of precision T-cell therapies in solid tumors. The report will be released after market close on November 8, 2022, with a conference call scheduled for November 9, 2022, to discuss the results in more detail.